Avtozma (Tocilizumab-Anoh): A New Biosimilar Expanding Treatment Options for Rheumatoid Arthritis and Other Inflammatory Diseases
The approval of biosimilar medicines continues to transform the treatment landscape for autoimmune disorders, making advanced biologic therapies more accessible to patients worldwide. One of the newest additions is Avtozma, a biosimilar version of Actemra developed by Celltrion. In January 2025, the U.S.